Ottawa, ON – Innovative Medicines Canada (IMC) congratulates Mark Carney on his election as Canada’s Prime Minister, the Liberal Party on forming government, and all elected Members of Parliament in the April 28 federal election.
Representing Canada’s pharmaceutical industry, IMC is committed to working collaboratively with the new government to strengthen the economy by improving access to medicines and growing the country’s life sciences ecosystem. IMC members support over 100,000 jobs and contribute up to $16 billion annually to Canada’s economy.
“Healthcare remains a top priority for Canadians, and we are encouraged by the Liberal Party’s platform commitments to support innovation and entrepreneurship, cut red tape, reduce wait times for access to innovative, life-saving medicines and vaccines, and modernize our public healthcare system,” said Bettina Hamelin, President of IMC.
“We look forward to partnering with the new government to help achieve these goals and ensure Canadians receive the treatments they need, when they need them,” Hamelin added.
In the coming weeks, IMC will reconnect with the government’s key decision-makers and departmental staff to advance shared healthcare goals, including:
- Reducing wait times for public access to life-saving medications following Health Canada approval, by cutting red tape without lowering safety standards.
- Incentivizing investment in innovation and securing Canada’s advantage in strategic industries like biomanufacturing by supporting companies in the biotech industry.
- Enhancing Canada’s life sciences leadership and improving patient access to new therapies by attracting top talent to Canadian research institutions.
IMC is committed to being a collaborative partner in shaping policies that prioritize patient access to innovative treatments, support scientific advancement, and reinforce Canada’s life sciences sector as a globally competitive economic driver. Working together will ensure Canadians benefit from timely access to the latest medical innovations, while Canada continues to attract investment, research, and talent in this vital sector.
About Innovative Medicines Canada
Innovative Medicines Canada (IMC) is the national association representing Canada’s innovative pharmaceutical industry. The industry proudly supports over 100,000 high-value jobs, contributes a total of $16 billion to the economy, sponsors the majority of clinical trials in Canada, and invests close to $3 billion in research and development each year. IMC advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians. The association and its members are committed to being solutions-oriented partners in Canada’s healthcare system and have contributed over $30 million towards applied health systems research through the Health Research Foundation (HRF). Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
For further information:
Media Relations
E-mail: media@imc-mnc.ca
